| A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA) |
Ongoing |
Tozorakimab (MEDI3506) |
3 |
D9185C00001 |
King Abdulaziz Medical City NG (Jeddah), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| REFINE: Regorafenib observational study in hepatocellular carcinoma |
Ongoing |
Stivarga (regorafenib) |
4 |
19244 |
King Fahad Specialist Hospital (Dammam), King Khalid University Hospital (Riyadh),King Fahad Medical City (Riyadh),King Fahad Medical City (Riyadh),King Fahad Medical City (Riyadh), My Clinic (Jeddah) |
| A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) |
Ongoing |
BI 1015550 |
3 |
1305-0023 |
King Faisal Specialist Hospital and Research Center (Riyadh) , King Abdulaziz Medical City NG (Riyadh) , King Abdulaziz University Hospital (Jeddah),King Fahad Specialist Hospital (Dammam) |
| A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST) |
Ongoing |
BIIB059 |
2/3 |
230LE301 |
King Faisal Specialist Hospital and Research Center (Riyadh) , King Khalid University Hospital (Riyadh) |
| An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease |
Completed |
ribociclib / letrozole |
3b |
CLEE011A2404 |
NGHA-R , KFSH&RC-R , KFSH , KAMC , NGHA-J , KFMC |
| " A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer" |
Completed |
LEE011 (Ribociclib) |
3 |
CLEE011E2301 |
KKUH , KFSH & RC-R , NGHA-R , NGHA-J |
| Multicenter, open-label, study to evaluate safety,tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared with enalapril in pediatric patients from1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction) |
Completed |
Entresto |
3 |
CLCZ696B2319 |
KFSH&RC-R , KFSH-D |
| A Retrospective Observational Non-Interventional Study (NIS) to assess Patient Characteristics and Healthcare Resource Use (HCRU) among COVID-19 Patients Receiving Treatment with Nirmatrelvir; Ritonavir (PAXLOVIDTM) in the Kingdom of Saudi Arabia (KSA) |
Ongoing |
Paxlovid |
4 |
C4671054 |
King Faisal Specialist Hospital and Research Center (Riyadh) , King Faisal Specialist Hospital and Research Center (Jeddah) , King Abdulaziz Medical City NG (Riyadh) , King Abdulaziz Medical City NG (Riyadh) |
| Stroke and High-risk TIAs Outcomes with Reduction of Treatment duration in Emergency Rooms. (SHORTER-Study). |
Ongoing |
PLAVIX Clopidogrel 75 MG TABLET |
3 |
1 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Medical City (Riyadh),King Faisal Specialist Hospital and Research Center (Jeddah) |
| A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension, Followed by an Open-label Treatment Period With Macitentan 75 mg. (UNISUS) |
Ongoing |
Macitentan |
3 |
AC-055-315 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Medical City (Riyadh) |
